Tirzepatide and retatrutide: two receptor counts, two completely different regulatory positions

These two compounds get discussed as though they sit on a single ladder — two receptors, then three; good, then better. They do not. The difference that matters most between them is not pharmacological at all. One is an approved medicine with a licence, a label and a dossier behind it. The other is an investigational compound that no regulator has authorised.

Everything else in this comparison is secondary to that, so it goes first.

The regulatory position, stated plainly

Tirzepatide is approved. It is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management, and in December 2024 the FDA additionally approved Zepbound for moderate-to-severe obstructive sleep apnoea in adults with obesity. Those are real licences, granted after review of a full dossier, and the medicine is prescribed and dispensed through pharmacies.

Retatrutide is not approved anywhere, for anything. It is Eli Lilly's investigational triple agonist, developed as LY3437943. Phase 2 results were published in 2023 and the first phase 3 results in late 2026. Published trials are not an authorisation.

That asymmetry is the whole reason the comparison people want — which one works better — cannot be answered from the literature. No trial has randomised anyone to one against the other.

What each trial programme examined

Tirzepatide: SURPASS and SURMOUNT. SURPASS tested it across type 2 diabetes with HbA1c as the primary endpoint. SURPASS-2 is the one worth knowing, because it is a head-to-head against semaglutide rather than against placebo: 1,879 participants over 40 weeks, reporting HbA1c reductions of 2.01 to 2.30 percentage points across tirzepatide groups against 1.86 with semaglutide, with tirzepatide non-inferior and superior at all three doses tested (PMID 34170647). The margins are small in absolute terms and statistically clear, which is how an incremental class advance usually looks.

SURMOUNT carried it into obesity with body weight as the endpoint. SURMOUNT-1 randomised 2,539 adults with obesity, or overweight plus a weight-related complication and without diabetes, over 72 weeks, and reported mean weight changes of −15.0%, −19.5% and −20.9% across the three dose groups against −3.1% on placebo (PMID 35658024). Adverse events were predominantly gastrointestinal and concentrated during dose escalation.

Retatrutide: phase 2, then TRIUMPH. The phase 2 obesity trial enrolled 338 adults over 48 weeks and reported mean weight change up to −24.2% against −2.1% on placebo, along with dose-dependent heart-rate increases that peaked at 24 weeks (PMID 37366315). A separate phase 2 trial in type 2 diabetes measured HbA1c against both placebo and dulaglutide (PMID 37385280). Phase 3 TRIUMPH-1 then randomised 2,339 adults with obesity over 80 weeks, reporting mean weight change up to −25.0% against −3.9% on placebo, and also measured knee osteoarthritis pain and the apnoea–hypopnoea index in prespecified subgroups (PMID 42814954).

Why you cannot stack those percentages against each other

It is tempting, and it is wrong. −20.9% at 72 weeks and −25.0% at 80 weeks were produced in different trials, with different enrolment criteria, different durations, different baseline weights, different dose-escalation schemes and different handling of participants who stopped. Cross-trial percentage comparison is the single most common error in writing about this class, and sellers make it constantly because it produces a conclusion that sells the unapproved compound.

The honest statement is narrower: both programmes reported substantial mean weight reduction against placebo in the populations they enrolled, and the retatrutide trials reported larger point estimates than the tirzepatide trials did. Whether that difference would survive a randomised head-to-head is unknown, because no such trial has been published.

The third receptor, and what it costs

The pharmacological difference is glucagon. GLP-1 and GIP are incretins; adding GIP to GLP-1 was tirzepatide's step. Glucagon is retatrutide's, and it is counterintuitive, because glucagon's textbook role is to raise blood glucose. The rationale is its action on hepatic fat handling and energy expenditure, with the two incretin arms covering glycaemic control — which is exactly why the phase 2 diabetes trial made HbA1c the primary endpoint rather than an afterthought.

Three receptors is not automatically better than two. It is more surface area for effects you want and for effects you do not, and the long-term consequences of chronic glucagon-receptor agonism in people are not characterised. Tirzepatide's dossier includes years of post-approval use across large populations. Retatrutide's does not exist yet.

What a research chemical is, and is not

Both compounds are sold here as laboratory material, and for both the same thing is true: it is not the medicine.

For retatrutide there is no medicine to confuse it with — nothing is approved. For tirzepatide there is, which makes the distinction more important rather than less. Mounjaro and Zepbound are manufactured to a licence, released against a specification filed with a regulator, prescribed by a clinician and dispensed by a pharmacist, with that whole chain accountable for the result. Research-chemical tirzepatide is none of those things. It carries no prescription, no pharmacist, no label approved by anyone, and no legal status as a medicine in Canada or anywhere else. Buying the same molecular formula does not buy the medicine, because almost everything that makes a medicine a medicine is the system around the molecule.

Both are supplied here as lyophilised powders for laboratory use: Tirzepatide and Retatrutide. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Reconstitution is arithmetic and nothing more: a 10 mg vial taken up in 2 mL of bacteriostatic water is 5 mg/mL. That division is the only calculation this site publishes, and it is not a protocol.

For the receptor biology in more detail, see Retatrutide and the triple agonist idea.

Common questions

Can I use either of these to lose weight? No. What is sold here is research material for laboratory use — not a medicine, not a prescription, not a weight-loss product. For retatrutide there is no approved use anywhere to follow. For tirzepatide an approved medicine does exist, and this is not it: the approved product comes from a licensed manufacturer through a prescription, with a clinician monitoring the person taking it. If weight or diabetes is a medical question for you, it belongs with a clinician, who has licensed options.

Is retatrutide the next generation of tirzepatide? That framing assumes a result the literature has not produced. Retatrutide is a later molecule with an additional receptor target and, so far, larger point estimates in separate trials. It is also unapproved, with a shorter safety record and open questions about heart rate and about chronic glucagon-receptor agonism. "Later" and "better" are different words.

Why is there no head-to-head trial? Partly timing — retatrutide's phase 3 programme was designed against placebo, which is what registration requires. Partly incentive: both compounds are Lilly's, and a sponsor has little reason to randomise its approved medicine against its own candidate. It may happen. It has not been published.

Does the higher purity figure on one product mean it is better? Purity figures describe a specific lot of chemical, measured by a specific laboratory, and they are stated per lot on the product pages for exactly that reason. They say nothing about whether a compound is approved, safe or suitable for anything, and they are not a substitute for the regulatory status set out above.

Selected Research References

1. Frías JP, Davies MJ, Rosenstock J, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. pubmed.ncbi.nlm.nih.gov/34170647
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. pubmed.ncbi.nlm.nih.gov/35658024
3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. pubmed.ncbi.nlm.nih.gov/37366315
4. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Phase 2 Trial Conducted in the USA. The Lancet. 2023;402(10401):529-544. pubmed.ncbi.nlm.nih.gov/37385280
5. Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42814954

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.